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ABSTRACT
The workshop on Three Rs Approaches in the Production and Quality Control of Fish Vaccines aimed
a) to identify animal tests currently stipulated for the production and quality control of fish vaccines and to
highlight animal welfare concerns associated with these tests; b) to identify viable options to replace,
reduce, and refine animal use for fish vaccine testing; and c) to discuss the way forward and set out how
the Three Rs may be implemented without jeopardizing the quality of the vaccines. The workshop
participants -- experts from academia, regulatory authorities, a scientific animal welfare organization, and
the fish vaccine industry -- agreed that efforts should be undertaken to replace the vaccination challenge
batch potency testing with tests based on antigen quantification or antibody response tests. Regulatory
requirements of questionable scientific value and relevance for the quality of fish vaccines, such as the
re-testing of batches produced outside Europe, or the double-dose batch safety test, should be reconsidered. As an immediate measure the design of the current animal tests should be evaluated and
modified in the light of refinement and reduction, for example, the number of unprotected control fish in
vaccination-challenge tests should be reduced to the minimum.

1. Introduction
The European Centre for the Validation of Alternative Methods (ECVAM) organized a workshop on Three
Rs Approaches in the Production and Quality Control of Fish Vaccines. The workshop took place on
29e31 January 2008 in Ispra, Italy. The main objectives of the workshop were a) to identify animal tests
currently stipulated for the production and quality control of fish vaccines and to highlight animal welfare
concerns associated with these tests; b) to identify viable options to reduce, refine and replace animal
use for fish vaccine testing; and c) to discuss the way forward and set out how replacement, reduction
and refinement (Three Rs, [1]) may be implemented more actively.
Driven by remarkable successes in disease prevention and control, there is a significant increase in
vaccination against bacterial and viral infections in European aquaculture, and a corresponding increase
in vaccine supply to European markets. According to current regulatory guidelines, in vivo methods are
still dominating the evaluation of current and new vaccines for fish. Consequently, there is an increase in
the number of fish used during the development, licensing and quality control of fish vaccines. In Norway,
which is the leading producer of farmed salmonids and the major user of fish vaccines in Europe, this has
led to fish outnumbering all other animal species used for biomedical research [2]. Furthermore,
regulatory requirements stipulate immunization challenge tests to demonstrate the efficacy of fish
vaccines, and such tests are also recommended to confirm potency before batch release. Because
unprotected fish will develop disease and illness during such tests, these procedures are of greater
concern with respect to animal welfare than those which do not involve experimental challenge (e.g.
serological tests). The potential for adverse reactions, and for test procedures to cause pain, suffering
and distress, applies to fish in the same way as any other species.
In this context, experts from academia, regulatory authorities, a scientific animal welfare organization and
the fish vaccine industry participated in the workshop, contributing unique scientific data, their personal
experience, scientific skills and judgment. At the time of writing, several essential aspects relevant to
animal welfare in fish are scarcely researched or may be subject to divergent interpretation (e.g. the
nature of pain sensation and cognition in fish). However, the participants agreed on two overall goals. The
first was to focus on how replacement, reduction and refinement of animal tests [1] could be further
implemented particularly regarding procedures perceived as the “most severe”. The second was to
explore how animal tests of questionable relevance could be avoided in the production and quality control
of fish vaccines.
Before presenting the outcome of the workshop, background information is provided on relevant topics
such as the immune system of fish, the capacity of fish to experience pain, suffering and distress, and
current fish vaccine testing requirements. Each of these has implications for the importance of and/or
ability to implement the Three Rs concept in the quality control of fish vaccines.
1.1. The immune system of fish
The most prominent macroscopic differences between mammalian and teleost immune systems are the
location and distribution of relevant cells, tissues and organs, especially the sites for hematopoiesis. The
obvious differences are that fish lack bone marrow, lymph nodes and Peyer’s patches, and instead the
kidney is a major lymphoid organ in the teleosts in addition to the thymus, spleen and mucosa-associated
lymphoid tissues [3,4]. Primary lymphoid organs seem to be the thymus (T-cells) and kidney (B-cells) [5].
The foremost part of the kidney shows morphological similarities with the bone marrow in higher
vertebrates [6] but it also serves as a secondary lymphoid organ, and together with the spleen can be
viewed as a lymph node analog important in the induction and elaboration of immune responses [7]. It
appears that four out of the five classical inflammatory signs may be present in fish; swelling (tumor),

redness (rubor), pain (dolor), and loss of function (functio laesa) but being poikilothermic animals, heat
(calor) is not obviously associated with inflammation in fish. Mast-like cells (eosinophilic granule cells) are
present but lack histamine in their granules [8], however, they degranulate following intraperitoneal
injection with various phlogistic agents including mast cell degranulation agent 48/80 [9] suggesting that
they induce vascular changes. The humoral components of the innate immune system of fish are
numerous, with different functions and include growth inhibitors, various lytic enzymes, components of the
complement pathway, agglutinins and precipitins, natural antibodies, cytokines, chemokines and
antibacterial peptides. An overview of the innate immune system of fish can be found in [4,10]. The
current status of the adaptive immune system in fish has been recently reviewed [3]. The effector cells of
this system are two types of lymphocytes, B-cells that play the effector role in the humoral immune
response, whereas T-cells are intimately involved in cell-mediated immune responses. Alongside with the
lymphocytes is the presence of antigen presenting MHC class I and class II molecules however in all
teleosts studied so far including salmonids the MHC class I and II regions are unlinked [11].
The availability of well-characterized B cell-specific anti-IgM monoclonal antibodies (mabs) for many fish
species has facilitated more researchon B-cells compared to T-cells. Compared to mammals, fish B cell
responses differs in many aspects. They do not show an Ig class switch, and the only classes detected so
far is a tetrameric homolog of IgM as predominant serum immunoglobulin and two other types, IgD and
IgT [12-14]. In contrast to mammalians, B-cells from teleost fish show potent in vitro and in vivo
phagocytic activities [15]. Bonyfish respond however poorly to immunization compared to mammals as
they produce antibodies with lower affinity for the antigen as affinity maturation has not been detected in
fish [16].
Detailed functional studies of piscine T-cells in major aquaculture species are currently hindered due to
lack of antibodies for detection, but their presence can be concluded from functional studies and
expression of TCR, CD8 and CD4 genes [3]. Studies on cell-mediated cytotoxicity (CMC) activity in fish
are also hindered due to highly polymorphic MHC molecules [17] although experimental studies have
documented MHC-I restricted killing of virus infected target cells [18] and similar findings were reported
earlier in rainbow trout [19]. To what extent the T helper cell subdivision exists in fish is not known but
some of the cytokines reflecting both Th1 and Th2 responses have been found in salmonids, zebrafish,
and pufferfish.
The second key feature of the adaptive immune response is memory and albeit indications of the
existence of an immunological memory in fish [20], however, it is not definitively proven.
In conclusion, the marked differences between the mammalian and piscine immune systems and the
relative lack of specific reagents may serve to explain why fish vaccine testing still mainly relies on in vivo
methods, and why the development of alternatives based on serology or antigen quantification test is
slow.
1.2. Pain, illness and suffering in fish
If it is accepted that fish have an awareness of pain, it is important to understand how experimental
procedures may affect them, so that any suffering can be prevented or minimized [21]. This section
defines pain, for the purposes of this report, and discusses the evidence for pain perception and suffering
in fish as it is believed to occur during vaccine research and quality control. Pain can be defined as a
negative sensory and psychological experience. This splits pain into two components, where there is
(i) tissue damage giving rise to the sensation of pain and (ii) a negative subjective experience, or suffering
[22]. Judgments about the capacity of non-human animals to experience pain must be made for each
species using behavioral, physiological and neurological indicators as a basis. For example, some pain

research involves recording behavioral and physiological responses to a potentially painful event. If
normal behavior is suspended and negative or abnormal changes in behavior and physiology occur, then
it can be inferred that the animal is experiencing a negative affective state alongside the sensory
component.
There are a number of other techniques that can be used to deduce whether animals perceive pain.
Examples are investigating whether the species has the neural machinery (nociceptors) to detect noxious
stimuli that give rise to the pain sensation, whether analgesics reduce behavioral and physiological
responses to a potentially painful event, and whether animals can learn to avoid damaging stimuli.
1.2.1. Sentience, consciousness and cognition of pain
A number of studies have been conducted using the above techniques to assess the potential for
nociception and pain in fish. It has been shown that fish do have nociceptors that detect painful stimuli
[23], with physiological properties that are very similar to those found in mammals [24-28]. In several fish
species activity patterns differ when the animals are subjected to non-noxious stimuli as opposed to
painful stimuli [21,29,30]. The use of morphine in trout given a potentially painful stimulus decreased
anomalous behaviors and prevented the suspension of normal behavior [31]. Fish are capable of learning
to avoid noxious stimuli and this learning does not occur when morphine is administered, suggesting that
pain is reduced [32]. Finally, noxiously stimulated trout do not show an appropriate response to a fear test
and this suggests that pain dominates their attention and is therefore an important and unpleasant state
to the fish [33,34].
While there is evidence for nociception in fish, an animal has to be sentient or conscious in order to
experience pain. Sentience is the ability to perceive external stimuli and research has shown that fish can
sense potentially painful stimuli and that their behavior is negatively affected by such stimuli, therefore, it
could be argued they are aware of/can experience pain. “Higher order” forms of consciousness include
self-awareness, meta-cognition (having thoughts about thoughts and creating internal representations)
and finally episodic memory where animals can think about the past and future. Evidence for these higher
order forms have been demonstrated in birds, rats, dolphins and primates [35-39] but have never been
explored in fish and so it cannot be stated for certain that they do or do not exist.
Therefore, the participants in the workshop do not propose that fish have a similar experience of pain to
humans, but conclude that fish do experience noxious stimuli in a way that has a detrimental effect on
their behavior, physiology and well-being. It is therefore important that fish are treated in a humane
manner, including during experimentation. In the case of vaccine research and quality control, this
especially means minimizing and alleviating any pain caused by procedures that might cause tissue
damage or by illness that may develop.
Inferring from human experience, one can argue that most generalized infections are not painful per se.
Suffering is mainly associated with a general feeling of weakness and poor wellbeing, abnormality in
physiological functions, negative feelings and anxiety, including the fear of permanent disability or death.
Thus it appears that suffering in many illnesses is closely associated with the cognitive and mental
capacities of the sufferer. For the purpose of this report, however, and irrespective of potentially different
views upon the mental capabilities of fish, it was agreed that inflicting a generalized infection upon
experimental fish should be regarded as an invasive procedure with the potential to cause suffering.
Experimental infection may cause weakness, poor wellbeing, clinical illness, tissue damage and
eventually death. It is therefore important to be able to recognize signs of illness in fish so that humane
endpoints can be implemented if possible (see 4.4 Welfare assessment).

1.3. Animal tests stipulated for the production and quality control of fish vaccines
The regulatory authorities in Europe and North America stipulate animal tests to achieve approval for
marketing a vaccine and for batch (serial) release of the authorized vaccine.
A detailed description of the regulatory framework, the various requirements and animal tests are given in
Appendix A.
The various tests are briefly summarized and the minimum numbers of animals required are listed in
Table 1.
1.3.1. Efficacy testing (prior to product marketing authorization)
Fish of the target species are vaccinated in the conditions to be recommended for use. They are
challenged together with the unvaccinated control fish via a specific route and at a fixed interval after
vaccination. The fish are observed until at least a given percentage of specific mortality is reached in the
control group. The relative percent survival (RPS) values are calculated and have to meet the specified
regulatory requirements.
1.3.2. Safety testing (prior to product marketing authorization)
The safety of fish vaccines for all recommended uses has to be demonstrated under laboratory and field
conditions. Fish are vaccinated and, for a given period, observed for local and systemic reactions.
1.3.3. Batch (serial) potency testing
Batch/serial potency can be either by a vaccination-challenge test (as described above) or an antibody
induction test, for which fish are vaccinated and the level of antibodies induced is measured with
immunochemical methods. Under certain conditions, in vitro methods (e.g. antigen quantification) can be
used for serial potency testing in the US.
1.3.4. Batch (serial) safety testing
According to the European Pharmacopoeia (Ph.Eur.) monographs and European guidelines, the batch
safety test is carried out with a double dose of the vaccine administered to fish by the recommended
route and observed for a given period. No fish should show notable signs of disease or die from causes
attributable to the vaccine. As stated in the Ph.Eur. general monograph on veterinary vaccines, the
routine application of the batch safety test can be waived for established vaccines in agreement with the
competent authority provided that consistency of production has been demonstrated for at least 10
consecutive batches.
Batch (serial release) safety testing of fish vaccines in the US may be conducted by observation of fish
after vaccination during vaccination-challenge or vaccination-serology studies. Separate batch safety
studies in fish are required when potency is demonstrated by in vitro methods or in a non-target host (i.e.
in a species other than that for which it is recommended).
2. Potential for replacement
The highest number of experimental fish is currently being used during the quality control of fish vaccines
prior to batch release. Replacing in vivo with in vitro methods for quality control of commercial batches of
vaccines therefore has the potential to significantly reduce the numbers of fish used.

Following the consistency approach ([40], see also below), the focus of development and licensing,
including the documentation of safety, may be shifted toward a more comprehensive documentation of
both, acute and chronic systemic and local reactions. The demonstration of consistency with regard to
product safety and efficacy, along with prioritized development and validation of alternative potency test
methods, would allow for the total replacement of animal testing for batch release. If an alternative
potency test method can be validated before full licensing, there would even be an opportunity for the
elimination of animal testing in the demonstration of product stability.
Table 1. Minimum numbers of animals stipulated for the tests required in Europe and North America.
Ph.Eur.

EU
guidelines

Canada

USA

Prior to product approval
for marketing
Efficacy

200

Not given

100 fish per challenge organism

Usually at least 3
replicates of 50, 150
total

Safety
Laboratory

50

Not given

0 (carried out in combination with,
i.e. pre-challenge part of the
efficacy)
no minimum, require safety testing
of multiple serials at multiple
a
geographical locations)

0 (carried out in
combination with
efficacy)
1000

Not given

50 fish per challenge organism. In
vitro potency acceptable if properly
validated

In vitro potency
allowed for batch
release; challenge or
serology allowed but
not required

30 or 50

0 (carried out in combination with
efficacy, i.e, pre-challenge part
of the efficacy)

25

Field

180 or a sufficient number
of fish distributed in not
fewer than 2 sets of
premise

Batch/serial testing
Potency
Challenge
Serotology

60

Safety

10

35

2.1. Batch potency testing alternatives based on antigen quantification
New concepts of quality control can offer alternatives to current vaccination-challenge models.
The “consistency approach” is based on the principle that the extent of vaccine batch release testing
should reflect the level of consistency achieved during the production process. It implies the use of a set
of in vitro measurable parameters (e.g. antigen content and integrity) to constitute a product profile that
can replace or reduce current release tests. This product profile ensures that each batch is in diverse
aspects similar to a manufacturer-specific vaccine of well-documented efficacy and safety. Monitoring of
physiochemical parameters (e.g.pH value, viscosity, amount of inactivating and/or preservative agents)
will serve to verify consistency of the production process [40]. Gains need to be made to consider batch
potency by antigen quantification on the key attributes for an acceptable test. There may be an improved
validation potential, increased reproducibility, differentiation of potent from sub-potent batches, and utility
to employ the test throughout the shelf-life of the product in the same test system over models involving
animals.

A good alternative to a vaccination-challenge test would be to establish methods (e.g. ELISA) for relative
potency testing by antigen quantification. Such assays should be developed to measure an antigen or
antigens that are immunologically functional and can be quantified in the final product:
2.1.1. Technical considerations
a. The assay could be used both for in-process control and formulation, and also as a potency test
throughout the shelf-life of the product. Such an assay requires the use of a reference vaccine
which has been proven to be efficacious in the target animals. The ELISA would be standardized
to utilize specific antibodies to capture the antigen and quantify the concentration [41]. The
estimation of batch potency should be based on a “relative potency approach” and has to be in line
with the requirements outlined in Ph.Eur., Chapter 5.3. “Statistical analysis of results of biological
assays and tests” [42].
b. The potential for modulation of other antigens in a multivalent formulation might not be captured in
every type of antigen quantification assay, but can be controlled with additional antigen-based
tests and specifications on the concentrations of all other antigens in a defined product. Tighter
specifications for quantification of bacteria or virus particles in vaccines by total particle counts
(cells or antigenic units) for example will make this more feasible.
c. The antigen quantification test should be validated according to VICH Guideline 2 [43]. During
validation it should be demonstrated that the chosen potency test is capable to distinguish
between standard and sub-potent batches on the basis of antigen content.
2.1.2. Physico-chemical considerations
d. Antigen recovery experiments will show, whether elution is required to quantify the antigen in
adjuvanted products. e. In addition, the batch control testing would also require an assay to
estimate the consistency of the final product formulation. Through the validation studies, potential
effects of antigen-adjuvant formulation such as modulation of the immune response, vaccine
deposition and slow release, or antigen presentation should be addressed.
f. The inactivating and/or preservative agents used in manufacture must be considered during
validation of an ELISA assay for antigen quantification. The agents may be present in the final
formulation of the vaccine and the effect and antigen retention capacity of those agents may
change over time.
2.1.3. Immunochemical considerations
g. The ELISA assay should employ a reference batch of Good Manufacturing Practice vaccine
produced to the antigen specification as described in the dossier for licensing. Samples of the
reference vaccine must be kept without degradation and a defined period for use of the reference
vaccine should be determined. Its stability should be monitored in regular intervals and appropriate
warning and action limits should be set. A replacing procedure should be established. The
reference vaccine would be made from an antigen where the dose and function were determined.
An immunogenicity study of the reference vaccine should be established by validation of potency
in an in vivo vaccination-challenge model as required in Directive 2001/82 as amended [44].
h. While the quantification of protective antigens is optimal, any antigen that is capable of creating an
immunological response may be relevant. During development phases, several methods could be
employed to define a protective or immunorelevant reference antigen for use in ELISA tests. The

antigen selection could be optimized by harvesting immunoglobulin from convalescent or
immunized target animals in an in vivo model. Using an immune complexing method with the
harvested antibody, one could isolate and enrich immunorelevant proteins from a cell lysate of the
vaccine preparation. Further isolation of key antigens could be done using 2D electrophoresis gels
for identification of single proteins that might be further characterized by mass spectrometry. Other
serological evaluations such as immunoblotting could also be used to capture immunorelevant
antigens to select for a monitoring antigen in an alternative assay using monoclonal or polyclonal
antisera.
i. Where antigens in the vaccine are derived from crude cell lysates or whole cell preparations, the
use of polyclonal sera could also be used in anantigen quantification assay to measure the relative
quantities of all immunorelevant antigens without specific characterization. The rationale of a batch
potency test is to demonstrate consistency of antigenic properties and an immunological function
achieved by an immunological assay. For each test, the specific criteria that the products have to
meet for antigen quantification would need to be determined. These specifications may need to be
determined on a per product basis because no internationally standardized reagents are available
now or in the foreseeable future.

Recommendations:
•

•

Regulators should encourage the development, validation and use of antigen quantification
methods for batch potency testing and incorporate them into the respective guidelines and
monographs.
The potential of the consistency approach and its application to the batch testing of fish vaccines
should be evaluated.

2.2. Waiving the use of primary cell lines for extraneous agent testing of master seeds
The participants in the workshop believe that for the development of a fish vaccine, the use of fish to
isolate de novo primary cells for extraneous agent testing of master seeds should not be required. The
use of animals to create this primary cell culture(with the need to recover tissues from multiple fishes,
multiple times in order to gain the number of cells required at a low passage number) does not make
scientific sense. The interpretation of the relevant guidance documents [45] by medicinal authorities is
that there needs to be testing of the master cells and seeds on a primary cell line from the species of
origin. A primary cell line is one which is described as only one and preferably no more passages from
the primary isolation. An argument for the use of primary cell lines is that unknown extraneous viruses
could be better detected because primary cell lines contain a more diverse range of cell types, thus
(potentially) increasing the chance that at least one of them may be permissive. However, even primary
cell lines are normally of one cell type (such as epithelioid cells) and will thus not provide additional
probability of extraneous agent detection. For fish, especially for salmonids, there are several continuous
cell lines from the species of origin that could be used to test for extraneous agents. Any cell culture used
for extraneous agent testing should ideally itself be shown to be free of extraneous agents, which is not
possible when using primary cell cultures.
Recommendation:
•

Continuous cell lines should be allowed for extraneous agent testing of master seeds.

3. Potential for reduction
The greatest potential to reduce the number of fish used for fish vaccine testing lies in the omission of
certain tests that are of doubtful value to assure the quality, efficacy or safety of the products. These are
discussed below.
Apart from this, high priority should be given to reducing the numbers of fish subjected to the most severe
procedures or to procedures inflicting clinical illness on the experimental animals. Most likely these are
the control fish in vaccination-challenge tests, since they are unprotected and are -- by the very nature of
the test -- expected to develop disease and, if it is not possible to implement humane endpoints, they may
eventually die as a result.
Recommendation:
•

Priority should be given to reducing the numbers of fish subjected to procedures that may cause
severe outcomes.

3.1. Re-testing for batch release in Europe only when scientifically justified
Current European legislation requires that for veterinary medicinal products produced outside the
European Economic Area, each batch imported to a Member State must undergo a full qualitative
analysis, a quantitative analysis of at least all the active substances, and all other tests or controls
necessary to ensure the quality in accordance with the requirements of the marketing authorization [44].
There is no scientific rationale for this when it comes to most fish vaccines imported into Europe, bearing
in mind that target species and breeds (Atlantic salmon, rainbow trout) as well as the environmental
conditions may be identical or essentially similar in Europe as in the country of origin. Acceptance of
batch safety and potency data generated in the country of origin would therefore have a significant
potential for reducing the overall numbers of fish used for fish vaccine testing.
Recommendation:
•

Vaccines produced outside the European Economic Area should be re-tested for batch release in
Europe only when scientifically justified. Alternatively, the manufacturers from outside Europe
should organize that batches intended for the European market are tested only once at a certified
testing site within the European Economic Area.

3.2. Documentation of product safety for licensing
It is necessary to fully assess and document the safety of a vaccine during product development. This
requires extensive investigations on toxicological, systemic and local reactions, behavioral and
physiological parameters, feeding, and growth. At present, double-dose safety trials are a legal
requirement for the licensing of an inactivated fish vaccine. However, the benefits of double-dose trials vs.
single-dose experiments to yield relevant safety data have been questioned. If samples and observations
from single-dose experiments are shown to yield satisfactory safety documentation, relevant dual purpose
data (safety and efficacy) could be derived from the same single-dose experiments.
Recommendation:
•

The Ph.Eur. monograph requirements for documentation of target animal vaccine safety should
be re-assessed for fish vaccines, giving consideration to the VICH Guideline 44, that was adopted
during 2008 [46].

3.3. Safety testing for batch release
The current European requirements stipulate a double-dose target animal batch safety test (TABST) in at
least 10 fish (according to Ph.Eur. monographs) or at least 30 fish (according to EU guidelines). The
reasoning behind this discrepancy remains unclear. The EU guideline on specific requirements for fish
vaccines is currently under revision and this issue should be addressed during the revision.
Since 2005, the Ph.Eur. general monograph on veterinary vaccines [47] allows waiving of the batch
safety test for established vaccines in agreement with the competent authority provided that consistency
of production has been demonstrated for at least 10 consecutive batches. The CVMP has further
elaborated this issue in its position paper on data requirements to remove the TABST [48]. Despite this
possibility of reduction, manufacturers are reluctant to apply it as outlined in a review document on animal
welfare progress in Ph.Eur. monographs [49]. Reasons for this are the lack of harmonization between
European competent authorities and with regions outside of Europe.
Recommendations:
•
•

European regulators should harmonies their criteria for waiving the batch safety test.
The VICH should work toward harmonization of the requirements for the batch safety test for
1
veterinary vaccines including fish vaccines.

In addition, the workshop participants suggested a different approach to batch safety testing, since the
current safety test in at least ten animals is not determinative for the safety of adjuvanted fish vaccines
and thus has questionable relevance for product quality. If single-dose testing would be allowed, data and
observations derived from the vaccination of animals as part of the current in vivo potency test could be
used for documentation of batch safety. For this purpose, specific parameters for recording safety
relevant outcomes of single-dose immunization would need to be developed and validated. This should
take into account the requirements outlined in the CVMP position paper “On data requirements for
removing the target animal batch safety test for immunological medicinal products in the EU” [48].
In cases where a validated antigen quantification method is employed for potency testing, a separate
single-dose safety test would have to be conducted for a certain number of consecutive batches to
demonstrate consistency of production.
Recommendation:
•

The approach to batch safety testing should be revised, i.e. if single-dose safety testing would be
possible, relevant data on safety could be obtained through observations of the single-dose
2
immunized fish used for batch potency testing.

3.4. Waiving animal use to document the seronegative status of test fish
There is currently a requirement to document that fish used for safety testing of certain vaccines are
seronegative. However, there are no reports describing the phenomenon of anaphylaxis in fish, nor of
other biological effects on adverse vaccine reactions induced by the presence of antibodies to vaccine
antigens [50]. In vaccines not based on toxoids, antibodies are considered unlikely to interfere with
tolerance. The relevance of the requirement to prove that fish are seronegative may therefore be
questioned. The omission of this requirement would, however have only a minor effect on reduction and
1
2

Ongoing activities to remove the target animal safety test from. Ph.Eur. monographs (status 2010).
Ongoing activities at VICH level on criteria for waiving the target animal safety test (status 2010).

refinement, because testing is normally performed on entire recruitment populations (from which fish are
drawn for multiple batch tests), and sampling is performed after sedation and stunning.
The requirement for documenting the seronegative status of fish to be used for potency testing of Vibrio
vaccines (or other vaccines against strictly marine pathogens) should be maintained only in cases where
the test animal population has been exposed to seawater. Test animals of strictly freshwater origin are
unlikely to have been exposed to these pathogens, and documentation to substantiate non-exposure to
saltwater systems should be deemed sufficient to waive this requirement.
Recommendations:
•
•

Documentation of the seronegative status of fish for safety testing should be eliminated from all
fish vaccine monographs as the serological status is considered irrelevant to safety.
Documentation of the seronegative status of fish for potency testing of strictly marine pathogens
(e.g. Vibrio spp.) should be waived when it can be demonstrated that test fish had not been
exposed to seawater.

3.5. Optimize vaccinated/control fish ratio
The monograph requirements stating the minimum number of fish to be involved in efficacy
documentation and batch potency tests should be re-assessed, aiming to minimize the number of
unprotected control fish without compromising the statistical power of the tests. This work could build
upon previous work addressing both statistical andbiological aspects of fish vaccination trials [50-52] and
should also include scrutiny of pass criteria such as the estimates of relative protection (RPS). A vast
amount of recordings could potentially be made available in anonymous form by fish vaccine
manufacturers, creating a unique database for retrospective analysis, and allowing the use of practical
experience as the basis for statistical assessment and optimization of test design.
Recommendation:
•

The potential to reduce the number of control fish used in vaccination-challenge tests for efficacy
and batch potency testing should be evaluated, since most of these unprotected fish are
subjected to development of disease and associated distress.

3.6. Use of genetically homogenous experimental fish strains
In several experimental animal species, the use of genetically homogenous animals (inbred strains) is
being employed to reduce within-group variability and thus to minimize the number of individuals
necessary for biomedical experiments [53]. While outbred populations of fish species such as salmon,
rainbow trout and carp are known to be immunogenetically diverse [54-56], inbred or isogenic strains of
major aquaculture species are not currently available. Thus, the use of inbred strains is unlikely to
contribute much to reduction in the near future. However, the workshop participants strongly encourage
innovative academic research to assess the principal potential of genetic homogenous fish for reducing
fish numbers in biomedical testing in the long-term perspective.
Recommendation:
•

Research should be conducted into (i) the potential to produce inbred strains of fish, and (ii) the
contribution that these strains could make to reducing fish use and improving scientific validity in
biomedical research, including vaccine development and production.

4. Potential for refinement
Refinement has been defined as “any approach which avoids or minimizes the actual or potential pain,
distress and other adverse effects experienced at any time during the life of the animals involved, and
which enhances their wellbeing” [57]. The concept of refinement thus means considering the animal’s
whole lifetime experience, not just reducing suffering during scientific procedures.
In the case of fish used in vaccine studies, important causes of suffering or poor welfare are the effects of
disease challenge, the side effects of vaccines (both predictable and unpredictable) and pain arising from
scientific or husbandry procedures. For example, besides undergoing an invasive procedure, fish
subjected to inoculation challenge will likely (even if fully or partially protected) be at least temporarily
affected by exo- or endotoxins of the inoculum, and of bacteriaemia/viraemia, with corresponding
physiological changes. At the other end of the scale, inoculation procedures performed under anesthesia,
for example single-dose or even double-dose immunization for safety assessment, are believed to cause
minimal pain or suffering in the experimental fish.
The participants in the workshop assumed that fish may experience pain as a result of tissue damage, but
the potential for fish to suffer due to the effects of toxins or disease has not been objectively evaluated at
the time of writing. Therefore, it was agreed that fish are given the benefit of the doubt and that inflicting
illness should be considered undesirable from an animal welfare viewpoint.
4.1. Batch potency testing alternatives based on serological methods
Serological methods (specific antibody response measurements) are a potential way of reducing the
number of fish routinely being subjected to experimental challenge procedures. The option is already
permitted in Ph.Eur. fish vaccine monographs. However, little progress has been made in the
development and validation of such alternative batch potency tests. A project group has recently showed
promising results in developing a batch potency test for oil adjuvanted furunculosis vaccines in Atlantic
salmon by antibody ELISA (AB Romstad, pers. comm. during this workshop). A time point for blood
sampling has been determined and the potential of the test to reveal sub-potent batches has been
evaluated. Further work is needed to investigate whether the method can be used for the testing of
multivalent vaccines, to evaluate intra- and interlaboratory variability, and to establish whether the
measured antibodies in themselves are protective (by passive transfer).
Especially for multivalent vaccines, up to six groups of fish used in parallel challenge procedures (one for
each vaccine antigen) could be saved by using the same blood samples from one immunized group to
confirm batch potency for all antigens. However, given the paucity of academic research on such tests
and the economic limitations of the fish vaccine market, the costs of developing and validating such
alternative batch test methodologies are prohibitive on a product-by-product basis. This work should be
encouraged and sufficient funding should be mobilized to develop and validate methods for such batch
tests and to provide the necessary reagents. This would stimulate vaccine manufacturers to adapt such
protocols by inclusion of product-specific key reagents (e.g. antigens for coating ELISA plates,
monoclonal antibodies, etc.).
Obviously, the use of serological methods would also contribute to the refinement of fish vaccine trials, as
the most invasive among the current trial procedures (experimental challenge) is no longer needed.
Recommendation:
•

Efforts should be undertaken to develop and validate serological methods for batch potency
testing.

4.2. Procedures
Procedures that may cause discomfort, pain or distress in fish vaccine studies include handling,
identification, administration of substances in the case of challenges by injection, and killing. Guidance on
refining some common procedures in fish can be found in the Canadian Council on Animal Care
“Guidelines on: the care and use of fish for research, teaching and testing” [58].
4.2.1. Analgesia/anesthetics/sedation
The use of analgesics, anesthetics and sedatives to reduce suffering during potentially painful or stressful
procedures in fish should always be given full consideration. Decisions on whether these agents will be
used should be based on judgment about the invasiveness of the procedure and the benefits of
anesthesia or analgesia against any potential harm associated with the analgesic, anesthetic or sedative
itself. For example, there may be trauma associated with delivery, side effects or recovery time. There is
also evidence that some anesthetic agents can be aversive and stressful to fish [59]. A range of potential
agents should be considered and expert advice sought in relation to their relative aversiveness,
refinements in delivery and whether there is evidence for or against any genuine impact on scientific
outcomes. Analgesia, anesthesia or sedation should be used whenever their benefits are considered to
outweigh the potential harms to the fish and their use will not compromise the science (For further
guidance see [58]).
Examples of procedures where analgesics, anesthetics or sedatives are often used in fish vaccine testing
are handling, identification, transport and euthanasia. The effect of analgesics on the immune response
has not been evaluated in fish, but it may be possible in many cases to allow the agent to wash out
before beginning scientific procedures. In addition, unrelieved pain will also have an effect on the immune
response and thus on animal physiology.
Recommendations:
•

•

Analgesics, anesthetics or sedatives should be used during any potentially painful procedure or
stressful event, whenever the benefits are predicted to outweigh any potential harm due to
administration trauma or side effects and the science will not be compromised.
More research is needed into the effects of sedatives and analgesics on the immune responses
of fish, to alleviate concerns about interference with study objectives.

4.2.2. Handling
Handling is likely to be highly stressful for fish, especially if netting and holding in air is involved. It may be
possible to avoid exposure to air, when transporting fish between tanks for example, by moving them in
containers in water-filled containers.
Recommendation:
•
•

Fish should preferably be kept in water whenever being moved
Exposing fish to air during handling and transport should be avoided wherever possible.

4.2.3. Marking methods and identification of fish
Marking individual fish for identification purposes will inevitably cause a degree of distress and discomfort,
because it involves capture and handling as well as applying the chosen technique. Table 2 lists currently
available techniques for identifying fish, with brief information to enable the least invasive technique to be

chosen that is compatible with the scientific aims, any requirement to reduce numbers and the equipment
and staff skills that are available (see also [58]).
Note that in some instances there can be a dilemma between refinement and reduction, for example
using Passive Integrated Transponder (PIT) tags for identification requires invasive procedures but can
enable the number of experimental animals to be reduced. In general, the aim should be to minimize
suffering and maximize welfare of individual animals even if more animals may be used.
Recommendations:
•

•

Identification is a potentially painful and distressing procedure and therefore current knowledge
about available techniques should be researched and the least invasive method chosen that is
appropriate, taking into account any potential to reduce animal numbers.
It should be ensured that everyone who will be marking fish is appropriately competent and
empathetic, has adequately functioning equipment and a realistic workload.

4.2.4. Administration of substances/challenge organisms
Substances or challenge organisms may be administered to fish using a number of routes in vaccine test
studies such as injection, orally and by immersion. Administration by injection involves handling stress,
the discomfort of the injection, possible pain due to tissue distension or the physico-chemical nature of
the substance or challenge organism, and potential adverse after-effects of the substance or organism
[60]. Less invasive administration techniques are to be preferred wherever possible; for example,
infecting a small number of fish via waterborne exposure (ideally cohabitation) and allowing them to
challenge other test fish is a commonly used refinement in vaccine studies. Fewer animals might be
affected by toxic components of the challenge organism and/or temporary or permanent
bacteriaemia/viraemia when administration is done via the water, compared to administration via
inoculation. General guidance on refining the administration of substances was published by Morton et al.
[61] and the CCAC [58].
Recommendations:
•
•
•

The least invasive or least stressful technique for administering substances or challenge
organisms to fish that is compatible with the aims of the experiment should be used.
Infection by immersion, bath or cohabitation should be considered as an alternative to invasive
administration techniques.
Ways to further refine the chosen method should be researched, for example by reducing needle
gauge, improving dosing technique or selecting a less irritant carrier.

4.2.5. Euthanasia
New EU legislation3 states tha tmost fish should be killed either by concussion of the brain by striking of
the cranium, or by an overdose of anesthetic using an appropriate route and anesthetic agent for the size
and species. Electrical stunning is permitted provided that specialized equipment is used. When killed by
anesthetic immersion, fish should be left in the solution for at least 5 min following the cessation of
opercular movement and/or vestibulo-ocular reflex. In both cases, death should be confirmed, for

3

At the time of the workshop the revision of Directive 86/609/EEC on the protection of laboratory animals
was ongoing (http://ec.europa.eu/environment/chemicals/lab_animals/home_en.htm). The new Directive
2010/63/EU on the protection of laboratory animals was published on 22 September 2010.

example, by physical destruction of the brain or exsanguination [62]. The relative humaneness of physical
and chemical methods, and the aversiveness of different anesthetic agents, has not been evaluated for
fish [63]. However, some techniques used for killing fish in non-laboratory settings are clearly inhumane
and should never be used in vaccine research, such as suffocation in air, chilling on ice or tearing gills
(See also [58,63] and the Norwegian School of Veterinary Science website; http://oslovet.veths.no/[click
on “fish” and “euthanasia”]).
Table 2. Techniques for marking individual fish.
Technique

Description

Welfare advantages

Welfare disadvantages

Dye or elastomer
injection

Small amount of dye, colored
polymer or colored latex injected
into the skin

Minimally invasive

Handling stress, injections may
be painful

Passive Integrated
Transponder
(PIT) tags

Small
“chip”
with
unique
identifying numbers inserted into
the body cavity or muscle using a
trochar or needle

Can lead to reduction -- allows
more sophisticated experimental
design;
potential
to
use
automatic
readers
so
no
subsequent handling required

Invasive technique into abdomen
or deep into tissues

External tags
(Floy-tags etc.)

Colored or numbered tag inserted
into musculature, often just below
dorsal fin

Can lead to reduction -- allows
more sophisticated experimental
design

Handling stress,
discomfort,
Permanent tissue penetration
may cause ulceration and
infection

“Tattooing”

Pigment is injected into skin cells
using high-pressure air device
(Panjet™)

Long-lasting,
rarely
causing
damage to dermal tissues

Can deteriorate over time
triggering need to be repeated

Freeze branding

Metal brand cooled to below 0˚C
held against the skin for 3-5 s

Long-lasting, no need for further
handling or reapplication

Causes tissue necrosis Not
recommended in cold water as
healing time increased and
secondary infections with
ulceration can occur

Fin clipping

Part of a fin is removed

Long-lasting, no need for further
handling or reapplication

Nociceptors are present on fins
so could be painful; Healing
may result in poor discrimination;
not recommended in cold water

Fin removal

An entire fin is removed

Long-lasting, no need for further
handling or reapplication

Invasive
handling
required

Adipose fin clip

Removal
of
appendage

Non-invasive
a
technique

Handling
and
anesthesia
required, allows only 2 groups

Fluorescent dyes of
scales

Immersion
substance

fluorescent

Non-invasive technique

Some handling required, few
groups only

Otolith marking using
rare
earth elements

Immersion or oral administration
of
marker
substance,
identification
by
biochemical
analysis

Non-invasive technique

Fish must be euthanized before
reading

a

adipose
in

fin

to

minimally

marking
and

technique;
anesthesia

Note: There was disagreement among workshop participants whether or not this technique could be considered non-invasive.

Recommendations:
•
•

It should be ensured that fish are only killed by concussion, anesthetic overdose or electrical
stunning as described above, by competent staff with an appropriate workload.
More research is needed into the humaneness of different techniques for killing fish of various
sizes.

4.3. Environment
There are two key components in providing fish with an appropriate environment that will facilitate good
health and welfare and minimize stress; (i) ensuring good water quality and appropriate water
temperature and (ii) providing a stimulating environment that will encourage a range of natural behaviors.
4.3.1. Water quality and water temperature
Good water quality is absolutely essential for ensuring fish health and welfare. General guidance on water
quality, including temperature and levels of oxygen, nitrogen compounds, carbon dioxide, pH and salinity,
can be found within EU legislation [62,64] and the CCAC guidelines [58]. Precise requirements can vary
between species and within the life cycle of individuals, so it is vital to research and provide the optimum
water quality for each species.
In salmonids, there is evidence that the side-effect potential of oil adjuvanted bacterin formulations may
unfold more rapidly and vigorously at higher temperatures, i.e. at 17˚C than at 10-12˚C [65]. However, by
elevating the water temperature, injection-site inflammatory lesions will be more severe. Research should
be carried out to investigate the potential benefits of changing the temperature recommendations, and
how this may lead to reduction in the number of fish used without compromising the power of these trials
to reveal unfavorable product characteristics, or batches falling outside the acceptable safety limits. Such
research should also address the ethical dilemma of reducing fish numbers vs. the potentially increased
severity of reactions in each test animal used.
4.3.2. Enrichment
Environmental enrichment has been shown to encourage a range of natural behaviors and reduce stress
in a range of species, which can have both animal welfare and scientific benefits. Enrichment commonly
provided for fish used in research and testing includes variable water flow, tank shading, variety of foods,
plants (real or artificial), species-appropriate substrate, refuges (e.g. terracotta pots, netting for fry,
artificial nests for breeding) and rocks [66,67]. However, there may be complicating factors in the field of
veterinary vaccine studies due to the need for stringent hygiene standards in some tests.
Despite constraints in some studies, it should still be possible to design an environment that affords a
degree of security and stimulation. For example, security can be provided for by adding refuges or by
covering the tank with a solid lid, including transparent areas or portholes to allow the fish to be observed
and monitored without lifting the lid. Fitting a lid can also help to reduce animal numbers, as fish will be
unable to jump out of the tank. Tinted tanks, artificial water lily pads and plastic plants are other options. It
is also important to research the natural biology and behavior of the test species when deciding on
appropriate enrichment; for example pelagic (schooling) and riverine (territorial) fish may have different
needs.
For further guidance on fish husbandry see: [58,68,69 and http://oslovet.veths.no/(click on “fish” and
“guidelines”)].

Recommendations:
•
•
•
•

It should be ensured that water quality and temperature are always within appropriate
physiological limits.
Species-appropriate environmental enrichment should be provided wherever possible.
Fish should be housed in appropriately sized and composed groups to facilitate species-specific
social behavior wherever protocols permit.
Restrictions on enrichment should be questioned and creative alternative approaches to provide
an appropriate environment should always be sought.

4.4. Welfare assessment
An essential part of refinement is better recognition and assessment of the causes and effects of animal
suffering. This helps to improve the prevention and alleviation of any pain, suffering or distress due to
procedures as well as other effects such as anxiety. Welfare assessment is heavily dependent on
interpreting animal behavior, but this can be especially difficult in the case of fish because their behavior
is very different from that of mammals. In addition, it can be difficult to monitor individuals if very large
numbers are housed together.
An effective welfare assessment system is essential for helping to identify behaviors that are a cause for
concern and for detecting signs of incipient suffering, thereby enabling humane endpoints to be
implemented (see below). The ideal system will include as many objective indicators as possible (e.g.
food consumption), consist of a small number of criteria that are easy to identify and avoid the observer
having to make a veterinary diagnosis as part of the assessment.
4.4.1. Signs of illness
In response to generalized bacterial or viral infections, fish often show an enhanced respiration rate (i.e.
more frequent opercular beats), reluctance to feed, abnormal (passive) behaviors and a reduction in
activity as the first signs of illness [26,30]. Other examples of clinical signs that are commonly used in
practice include skin color (especially darkened skin), red gills, decreased opercular beat rate, eye color,
physical injury, physical abnormalities and changes in oxygen demand [67]. Physiological indicators are
of limited use, because they are very difficult to measure without disturbing the fish, only a few have been
documented, and many of them depend on water temperature. Behavioral signs that could indicate
welfare problems include changes in levels of aggression, changes in swimming position, lethargy,
separation from the rest of the school and decreased avoidance of stimuli that would normally induce
anxiety. Very sick fish become unresponsive to external stimuli and usually float at the surface or sink to
the bottom of the tank. This can progress to a loss of equilibrium, with fish floating “belly up” as respiration
rate slows. At this stage mortality usually occurs (see section on humane endpoints, below). A detailed
list of clinical signs is given in the CCAC guidelines [58].
4.4.2. Behavioral indications for pain and suffering
Typical behavioral indicators of pain and suffering have been described for rainbow trout and zebrafish. In
rainbow trout, clear signs of a noxious, potentially painful event are an increase in opercular beat rate
from normal level of approximately 54 beats per minute to almost double (90e100 beats/min; [26]). This is
a larger rise than a stress response (which is approximately 70 beats/min). Zebrafish also show an
enhanced ventilation rate during nociception [30]. Trout perform anomalous behaviors such as rubbing of
an affected area, loss of equilibrium [30] head shaking and scraping against objects [67]. There is also a

dramatic decrease in activity in trout and zebrafish [30] but all of these changes show recovery from 3 to
6 h after the insult [33].
As in other experimental animals, observation and analysis of behavior is a valuable tool in research into
pain and welfare in fish. Inspired by Morton and Griffiths [70], Midtlyng [71] proposed a set of behavioral,
morphological, physiological and performance parameters to evaluate vaccination side-effects relevant to
fish welfare. Detailed guidance on the evaluation of clinical (including behavioral) signs to help assess on
the welfare of experimental fish has recently been published by the CCAC [58].
4.4.3. Welfare assessment in practice
Appendix B sets out an example of a welfare assessment system where numerical scores are assigned
to different criteria; an alternative is the “binary” score sheet where behavioral signs are simply marked as
present or absent.
A “team approach” is essential when designing and using any system for recognizing and recording
adverse effects. This requires input from researchers, animal care staff and veterinarians, all of whom
have different specialist knowledge and experience and can bring a different perspective. The team
should also regularly review the assessment system and adapt it as necessary to ensure that it is flexible,
effective, agreed on by all and usable by all. It is also important to maintain knowledge of new techniques
for observing animals, such as behavioral recognition software, other remote monitoring systems or
techniques for measuring metabolites in the water, so that these can be trialed and brought in whenever
feasible. Appropriate training and Continuous Professional Development is essential, which may include
specialist courses for those using and/or caring for fish. Staff levels should also be sufficient to ensure
that there is enough time to monitor fish effectively.
For further guidance on welfare assessment see: [58,64,71-73] and Appendix B.
Recommendations:
•
•
•
•
•

It should be ensured that a comprehensive welfare assessment system has been set up.
Subjective judgments about fish welfare and adverse effects are not always reliable in isolation.
Welfare assessment should be tailored to the protocol and regularly reviewed, using a team
approach.
Information on welfare assessment criteria and systems should be shared with other fish users,
e.g. in publications and at meetings.
Information on new techniques for welfare assessment is essential; trial and use new methods
whenever appropriate.
It should be ensured that there is sufficient staff with adequate time to monitor the fish effectively.

4.5. Humane endpoints
Humane endpoints are an essential component of humane science in all fields and there is scope to
implement humane endpoints in all vaccine studies, including those involving fish [74,58]. The Ph.Eur.
general monograph on veterinary vaccines permits humane endpoints [47] and the use of effective
welfare assessment systems, as outlined above, will facilitate their implementation. Considerable
progress has been made with respect to humane endpoints in mammals and the workshop participants
believe that fish deserve the same consideration.
However, there are some complicating factors in the case of vaccine testing and these need to be
addressed. There is generally a regulatory requirement to demonstrate a degree of morbidity in vaccine

tests, and it is necessary to be sure that animals are only killed if it is certain that they would have died as
a result of the disease challenge within the given observation period. In other words, the clinical signs that
determine the humane endpoint must be predictive of the required outcome of the test, e.g. mortality
within a given period, because too many “false positives” can render a study invalid. In fish vaccine tests,
even where endpoints have been defined, it can be difficult to identify fish that need to be euthanized in a
tank containing large numbers.
In practice, sick fish may not be identified until they have reached a moribund condition, which has been
described as a severely debilitated state that precedes imminent death. The moribund state is relatively
easy to identify, but it is considered not desirable on welfare grounds because of the suffering that the
animal will have experienced and may still be experiencing [75]. The general aim should be to reduce the
number of fish that become moribund in vaccine studies by increasing the implementation of effective
assessment systems and humane endpoints. However, in studies where challenge is by cohabitation it is
necessary to leave the moribund fish in to maximize infectivity. In this case, there is a dilemma between
allowing one fish to suffer vs. challenging all the fish by intraperitoneal injection.
Recommendations:
•
•
•
•

The use of death as an endpoint should always be questioned, especially if it is not a regulatory
requirement.
Refinement of humane endpoints should be actively sought and the number of fish reaching a
moribund state should be minimized within each study.
More research is needed into the identification of humane endpoints for fish in vaccine studies.
European Pharmacopoeia monographs for fish vaccines should specify typical clinical signs of
the disease, include validated criteria for humane endpoints wherever available, and discourage
death as an endpoint.

4.6. Training
All staff responsible for conducting procedures, monitoring fish and implementing humane endpoints or
otherwise euthanizing fish must be both competent and empathetic. This requires not only that they are
skilled in carrying out procedures, but also that they view fish as individuals, understand and accept that
they can suffer, and appreciate why fish welfare is important. Training should thus include: the biology
and behavior of the study species; recognizing and assessing both good welfare and signs of pain,
suffering or distress; and competence in all procedures that may be carried out including euthanasia
[76,77]. See also http://oslovet.veths.no/(click on “fish” and “education and training relating to fish
in research” and Appendix B). In addition, the University of Prince Edward Island offers a complete
training
program
for
people
who
use
fish
for
research,
teaching
and
testing
http://www.upei.ca/lifelonglearning/experimentalfish.
Recommendation:
•

It should be ensured that the relevant staff is trained to be empathetic, as well as trained to be
competent and knowledgeable about the species they are using and caring for.

5. Summary of recommendations
The participants in the workshop would like to encourage all stakeholders, manufacturers, regulators,
researchers and animal welfare officers to follow-up the recommendations of the workshop, which can be
summarized as follows:

5.1. Replacement
•
•

The use of antigen quantification methods for batch potency testing is being encouraged
according to the opportunities given in the respective guidelines and monographs.
Possibilities of applying the consistency approach to fish vaccine batch testing should be
evaluated.

5.2. Reduction
•
•

•
•
•

Fish vaccines produced in 3rd countries and imported to Europe should be only re-tested when
scientifically justified and the current practice of routine re-testing should be omitted.
Possibility of reducing the number of control fish in vaccination-challenge tests should be
evaluated, since most of these unprotected fish are subjected to development of disease and
associated distress.
4
European regulators should harmonize their criteria for waiving the batch safety test.
The VICH should work toward harmonization of the requirements for the batch safety test for
5
veterinary vaccines including fish vaccines.
Possibility of using single-dose protocols for batch safety testing should be discussed, which
4
would allow combination with the batch potency test.

5.3. Refinement
•

•
•
•
•
•
•

4
5

Efforts should be undertaken to develop and validate antibody induction methods for batch
potency testing, thus making vaccination-challenge tests obsolete. Funds should be made
available for this.
Death as an endpoint should be questioned whenever possible; humane endpoints should be
applied and moribund fish be humanely killed.
Less invasive administration techniques are to be preferred, e.g. waterborne exposure versus
intraperitoneal injection, and the least invasive techniques for identification should be used.
Welfare assessment criteria and systems for fish should be established and regularly reviewed in
a team approach.
Fish should be housed in species-appropriate social groups wherever protocols permit.
Suitable environmental enrichment and other husbandry refinements should be sought and
implemented.
Staff should be trained in welfare assessment of fish, e.g. be able to detect signs of illness (e.g.
change in skin color e especially darkened skin -, red gills, decreased opercular beat rate, eye
color, physical injury, physical abnormalities and changes in oxygen demand) as well as
behavioral changes (e.g. changes in levels of aggression and swimming position, lethargy,
separation from the rest of the school and decreased avoidance of stimuli that would normally
induce anxiety.

Ongoing activities to remove the target animal safety test from. Ph.Eur. monographs (status 2010).
Ongoing activities at VICH level on criteria for waiving the target animal safety test (status 2010).

Disclaimer
The views expressed in this article are purely those of the author and may not in any circumstances be
regarded as stating an official position of the European Commission.
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